Cargando…

The Potential Impact of Up-Front Drug Sensitivity Testing on India’s Epidemic of Multi-Drug Resistant Tuberculosis

BACKGROUND: In India as elsewhere, multi-drug resistance (MDR) poses a serious challenge in the control of tuberculosis (TB). The End TB strategy, recently approved by the world health assembly, aims to reduce TB deaths by 95% and new cases by 90% between 2015 and 2035. A key pillar of this approach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sachdeva, Kuldeep Singh, Raizada, Neeraj, Gupta, Radhey Shyam, Nair, Sreenivas Achuthan, Denkinger, Claudia, Paramasivan, Chinnambedu Nainarappan, Kulsange, Shubhangi, Thakur, Rahul, Dewan, Puneet, Boehme, Catharina, Arinaminpathy, Nimalan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488842/ https://www.ncbi.nlm.nih.gov/pubmed/26132584 http://dx.doi.org/10.1371/journal.pone.0131438

Ejemplares similares

Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis
por: Nair, Sreenivas Achuthan, et al.
Publicado: (2016)

Catching the Missing Million: Experiences in Enhancing TB & DR-TB Detection by Providing Upfront Xpert MTB/RIF Testing for People Living with HIV in India
por: Raizada, Neeraj, et al.
Publicado: (2015)

Enhancing TB Case Detection: Experience in Offering Upfront Xpert MTB/RIF Testing to Pediatric Presumptive TB and DR TB Cases for Early Rapid Diagnosis of Drug Sensitive and Drug Resistant TB
por: Raizada, Neeraj, et al.
Publicado: (2014)

Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India
por: Sachdeva, Kuldeep Singh, et al.
Publicado: (2015)

Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis
por: Khaparde, Sunil, et al.
Publicado: (2017)

Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population
por: Raizada, Neeraj, et al.
Publicado: (2015)

Feasibility of Decentralised Deployment of Xpert MTB/RIF Test at Lower Level of Health System in India
por: Raizada, Neeraj, et al.
Publicado: (2014)

The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis
por: Arinaminpathy, Nimalan, et al.
Publicado: (2020)

The number of privately treated tuberculosis cases in India: an estimation from drug sales data
por: Arinaminpathy, Nimalan, et al.
Publicado: (2016)

Tuberculosis treatment in the private healthcare sector in India: an analysis of recent trends and volumes using drug sales data
por: Arinaminpathy, Nimalan, et al.
Publicado: (2019)

Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness
por: Arinaminpathy, Nimalan, et al.
Publicado: (2021)

“Before Xpert I only had my expertise”: A qualitative study on the utilization and effects of Xpert technology among pediatricians in 4 Indian cities
por: McDowell, Andrew, et al.
Publicado: (2018)

Modelling the impact of effective private provider engagement on tuberculosis control in urban India
por: Arinaminpathy, Nimalan, et al.
Publicado: (2019)

Comparative Evaluation of GenoType MTBDRplus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Centre in India
por: Yadav, Raj N., et al.
Publicado: (2013)

Correction: Comparative Evaluation of GenoType MTBDRplus Line Probe Assay with Solid Culture Method in Early Diagnosis of Multidrug Resistant Tuberculosis (MDR-TB) at a Tertiary Care Centre in India
por: Yadav, Raj N., et al.
Publicado: (2013)

Predicting the impact of patient and private provider behavior on diagnostic delay for pulmonary tuberculosis patients in India: A simulation modeling study
por: Deo, Sarang, et al.
Publicado: (2020)

The Global Drug Facility as an intervention in the market for tuberculosis drugs
por: Arinaminpathy, Nimalan, et al.
Publicado: (2015)

A Multi-Site Validation in India of the Line Probe Assay for the Rapid Diagnosis of Multi-Drug Resistant Tuberculosis Directly from Sputum Specimens
por: Raizada, Neeraj, et al.
Publicado: (2014)

Source of Previous Treatment for Re-Treatment TB Cases Registered under the National TB Control Programme, India, 2010
por: Sachdeva, Kuldeep Singh, et al.
Publicado: (2011)

Catalysing progressive uptake of newer diagnostics by health care providers through outreach and education in four major cities of India
por: Raizada, Neeraj, et al.
Publicado: (2018)

Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
por: Fu, Han, et al.
Publicado: (2021)

The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis
por: Ricks, Saskia, et al.
Publicado: (2020)

Patient and Provider Reported Reasons for Lost to Follow Up in MDRTB Treatment: A Qualitative Study from a Drug Resistant TB Centre in India
por: Deshmukh, Rajesh D., et al.
Publicado: (2015)

Is One Sputum Specimen as Good as Two during Follow-Up Cultures for Monitoring Multi Drug Resistant Tuberculosis Patients in India?
por: Nagaraja, Sharath Burugina, et al.
Publicado: (2012)

Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement
por: Parmar, Malik M., et al.
Publicado: (2018)

Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation
por: Raizada, Neeraj, et al.
Publicado: (2018)

Accelerating access to quality TB care for pediatric TB cases through better diagnostic strategy in four major cities of India
por: Raizada, Neeraj, et al.
Publicado: (2018)

Cost and operational impact of promoting upfront GeneXpert MTB/RIF test referrals for presumptive pediatric tuberculosis patients in India
por: Sarin, Sanjay, et al.
Publicado: (2019)

Dynamics of Glycoprotein Charge in the Evolutionary History of Human Influenza
por: Arinaminpathy, Nimalan, et al.
Publicado: (2010)

New Vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access - “Reaching the un-reached”
por: Sachdeva, Kuldeep Singh, et al.
Publicado: (2012)

HIV Seroprevalence among Tuberculosis Patients in India, 2006–2007
por: Raizada, Neeraj, et al.
Publicado: (2008)

Upfront Xpert MTB/RIF for diagnosis of pediatric TB—Does it work? Experience from India
por: Kalra, Aakshi, et al.
Publicado: (2020)

The effects of a partitioned var gene repertoire of Plasmodium falciparum on antigenic diversity and the acquisition of clinical immunity
por: Recker, Mario, et al.
Publicado: (2008)

Effective use of a Limited Antiviral Stockpile for Pandemic Influenza
por: Arinaminpathy, Nimalan, et al.
Publicado: (2009)

Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor
por: Somasundaram, Sulochana, et al.
Publicado: (2013)

Management of tuberculosis by healthcare practitioners in Pakistan: A systematic review
por: Braham, Christy A., et al.
Publicado: (2018)

Viral Dynamics and Mathematical Models
por: Arinaminpathy, Nimalan, et al.
Publicado: (2014)

Combining serology with case-detection, to allow the easing of restrictions against SARS-CoV-2: a modelling-based study in India
por: Mandal, Sandip, et al.
Publicado: (2021)

Responsible travel to and within India during the COVID-19 pandemic
por: Mandal, Sandip, et al.
Publicado: (2021)

Plausibility of a third wave of COVID-19 in India: A mathematical modelling based analysis
por: Mandal, Sandip, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lvgc86hsr5ibclr7rdmcqh093v